Abeona SVP sells 12,050 shares to cover taxes

Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.

Accepted by SEC EDGAR 07/09/2026 - 07:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.

The company notes this sale was made to cover tax obligations from vesting of restricted stock awards. After the sale, O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock.

Insider Trade Summary

Net Seller: 12,050 shares

Net Sell 1 txn

Insider O'Malley Brendan M.

Role SVP, Chief Legal Officer

Sold 12,050 shs ($84K)

Share of Position Sold 2.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	12,050	$6.9637	$84K

Holdings After Transaction: Common Stock — 427,953 shares (Direct)

Holdings Before and After: Common Stock, 440,003 to 427,953 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 12,050 shares Weighted average sale price: $6.9637 per share Post-transaction holdings: 427,953 shares +1 more

4 metrics

Shares sold 12,050 shares Open-market sale on July 9, 2026

Weighted average sale price $6.9637 per share Common stock sale on July 9, 2026

Post-transaction holdings 427,953 shares Shares directly held by O'Malley after sale

Sale price range $6.86–$7.04 per share Prices for multiple transactions included in the sale

Key Terms

restricted stock awards, weighted average price, open-market sale

3 terms

restricted stock awards financial

"cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abeona Therapeutics (ABEO) insider Brendan O'Malley report on this Form 4?

Brendan M. O'Malley, Abeona Therapeutics’ SVP and Chief Legal Officer, reported selling 12,050 shares of common stock. The company states the sale was executed to cover tax obligations from the vesting of restricted stock awards.

How many Abeona Therapeutics (ABEO) shares did Brendan O'Malley sell and at what price?

Brendan O'Malley sold 12,050 Abeona Therapeutics common shares at a weighted average price of $6.9637. The footnote explains trades occurred in multiple transactions between $6.86 and $7.04 per share inclusive.

Why did Abeona Therapeutics (ABEO) insider Brendan O'Malley sell shares?

The company explains the reported sale was made to cover tax obligations related to the vesting of restricted stock awards. Such tax-cover transactions are typically mechanical and tied to compensation, rather than discretionary open-market portfolio moves.

How many Abeona Therapeutics (ABEO) shares does Brendan O'Malley hold after this transaction?

Following the reported sale, Brendan O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock. This shows he retains a substantial equity position in the company even after selling shares to satisfy tax obligations.

What trading range applied to Brendan O'Malley’s Abeona Therapeutics (ABEO) share sale?

The filing states the weighted average sale price was $6.9637 per share. Individual trades occurred in multiple transactions at prices ranging from $6.86 to $7.04 per share, with full trade breakdowns available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		S(1)		12,050	D	$6.9637(2)	427,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Brendan O'Malley	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)